| Autor: |
Lawrence D, Wagman, David A, Geller, Samuel A, Jacobs, Nicholas J, Petrelli, Carmen J, Allegra, Corey, Lipchik, Katherine L, Pogue-Geile, Ashok, Srinivasan, Ying, Wang, Michael J, O'Connell |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Journal of surgical oncologyREFERENCES. 126(8) |
| ISSN: |
1096-9098 |
| Popis: |
This study sought to determine the R0 resection rate in KRAS wild-type (WT), liver-only metastatic colorectal cancer (CRC) patients initially identified as having unresectable disease who were treated with FOLFOX7 plus cetuximab. Exploratory molecular analyses were undertaken before and after treatment.Twenty patients were enrolled. None had prior adjuvant chemotherapy. Cetuximab was added to a FOLFOX7 backbone and administered at 500 mg/mWe assessed the conversion rates from unresectable to resectable in hepatic-only, KRAS exon 2 WT mCRC. Seventeen of 20 patients undergoing chemotherapy were considered resectable by imaging criteria; R0 resection was achieved in 15/20 patients. Molecular profiling revealed heterogeneity between patients at the gene-expression, pathway signaling, and immune-profile levels.Although 15/20 (75%) converted to R0 resection, by 2 years, 10/15 R0 resections had recurred. Therefore, chemotherapy plus cetuximab is of limited long-term benefit in this setting. ctDNA analysis may guide additional therapy including immunotherapy. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Plný text